5% ophthalmic solution reported in the 804 facilities surveyed (safety population: N = 6686) Adverse Drug Reactions According to Patient Demographics and Dosing Frequency of Levofloxacin Table III lists the ADRs reported during the post-marketing surveillance of levofloxacin 0.5% ophthalmic solution,

according to patient demographics and the dosing frequency of levofloxacin. Of interest, the incidence of ADRs was significantly higher in females (0.82%) than in males (0.36%; p = 0.028), and eye irritation and eye pruritus were reported only in females. Of the 3904 women surveyed, seven were pregnant; none reported any adverse events with administration of levofloxacin 0.5% ophthalmic solution. However, no information pertaining to the effects of levofloxacin AZ 628 price 0.5% ophthalmic solution on labor or on the health of the newborn Crizotinib purchase was collected. Table III Adverse drug reactions associated with levofloxacin 0.5% ophthalmic solution, according to patient demographics and frequency of levofloxacin dosing There was no correlation between the age of the patient and the incidence of ADRs (table III). In patients aged <15 years, the incidence of ADRs was 0.32%, which was no higher than those reported in patients aged ≥15 and <65 years or in patients aged

≥65 years (0.62% and 0.81%, respectively). ADRs were found in four children: punctate keratitis (1 case), eye pruritus (1 case), dermatitis contact (1 case), and urticaria (1 case). No ADRs were reported in patients SB273005 supplier younger than 1 year old. As for the dosing frequency of levofloxacin, the incidence of ADRs did not differ significantly depending on the mean daily frequency of treatment with levofloxacin 0.5% ophthalmic solution. Efficacy Clinical Response A clinical response was observed in 95.5% of the 5929 patients included in the efficacy population. Response rates did not differ significantly between the three time periods of the survey Orotidine 5′-phosphate decarboxylase (p = 0.099, χ2 test). Clinical response was observed in 94.7% of patients

in the first time period, 95.9% of patients in the second time period, and 95.9% of patients in the third time period. Response Rates According to Disease Diagnosis The rates of clinical response to treatment with levofloxacin 0.5% ophthalmic solution are summarized in table IV, according to the type of external ocular bacterial infection that was reported. Cases where patients were diagnosed with two or more diseases were counted in each disease group. Response rates were similar for most types of external ocular infection; however, the response rate was 88.3% in patients who were diagnosed with dacryocystitis, which was significantly lower than the response rate observed in patients who were diagnosed with any other type of ocular infection (95.8%; p < 0.001). Table IV Rates of response to levofloxacin 0.